



Brussels, 31 October 2024
(OR. en, bg, de, es, fr, it, pl, pt)

Interinstitutional File:
2022/0345(COD)

14488/24
ADD 1 REV 4

CODEC 1937
ENV 999
SAN 589
COMPET 1020
CONSOM 303
AGRI 737

'I/A' ITEM NOTE

From:	General Secretariat of the Council
To:	Permanent Representatives Committee/Council
Subject:	Draft DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL concerning urban wastewater treatment (recast) (first reading) - Adoption of the legislative act = Statements

Statement by Bulgaria

Република България изразява загриженост относно значителните предизвикателства при прилагането на преработената Директива за пречистване на градските отпадъчни води, произтичащи от по-строгите изисквания за качеството на пречистените води и разширените задължения за мониторинг. Считаме за необходимо да се осигури гъвкавост на държавите при прилагането на Директивата, като същевременно се осигурят достатъчно механизми за подкрепа, които да улеснят прилагането ѝ, за намаляване на финансовата тежест за държавите членки и за защита на населението от повишаване на цените на услугите.

Макар договореният текст до голяма степен да отчита предварителните оценки за възможностите на страната за постигане на новите амбициозни изисквания, подчертаваме, че прилагането продължава да изисква огромни инвестиции и капацитет за развитието на канализационната мрежа, модернизацията на пречиствателните станции за отпадъчни води, контрола на индивидуалните и други подходящи системи и правилното управление. Въпреки удължените срокове и някои други промени, запазваме притеснения относно нужните финансови ресурси и време за реализация на съответните проекти в България, предвид повишаването на цените във всички сфери, изискващо актуализиране на прогнозните разходи и срокове.

Въпреки тези притеснения, България вижда необходимостта от опазването на околната среда и отчита приноса на акта в този аспект. Същевременно България подчертава, че има нужда от справедлив баланс между осигуряването на чиста околна среда и правото на равен достъп до здравеопазване, свързано с очакванията на пациента за наличие на безопасни, качествени и ефикасни лекарствени продукти на достъпни цени в ЕС. Разчитаме, че Европейската комисия ще работи, за да гарантира необходимата подкрепа на държавите членки, като подчертаваме нуждата от осигуряване на значителни средства от ЕС за изпълнение на високите нови изисквания.

Разпоредбите за разширената отговорност на производителя (РОП) имат потенциален негативен ефект върху конкурентоспособността на ЕС в глобален мащаб и привлекателността му като благоприятна среда за производство. Други потенциални негативни въздействия са ограничаване наличието на лекарствени продукти и съществено повишаване на себестойността и цените им, което е особено сериозен проблем за малки и средно големи държави като България. В този контекст потвърждаваме заявяваните в преговорния процес опасения, че тези разпоредби имат потенциал да въздействат върху наличността и цените на лекарствените продукти за българския пациент. Като производител на генерични продукти, България изразява тревога от потенциалния неблагоприятен ефект и върху конкурентоспособността на българската индустрия.

Приемането на акта и приключването на преговорите по досието не води до отпадане на тези притеснения за България. Запазваме многократно изразяваната в преговорите сериозна загриженост във връзка с разпоредбите относно РОП. Налице е причинно-следствена връзка между въвежданите с Директивата регулаторни изисквания и предвидимите негативни последици за индустрия, потребители и пациенти. Потенциалната индексация на цените на крайния продукт, съобразно въведените допълнителни финансови тежести, неминуемо ще бъде калкулирана към цената на продукта за крайния потребител, което, от своя страна, ще повлияе негативно на достъпността и удовлетвореността от терапията. Считаме, че трябва да се търсят механизми за справяне с антимикробната резистентност, но това не бива да се случва чрез оттегляне на производители и лекарствени продукти или чрез повишаване на цените.

България настоява да се вземат предвид икономическата осъществимост и допълнителна административна тежест за производителите на лекарствени продукти. Предвид новите данни за реалната стойност на необходимите инвестиции и очаквания ефект, настояваме за обективна оценка от Европейската комисия по прилагането на акта, включително относно реалната допълнителната финансова тежест за производители и държави членки. При потвърждение на опасенията на част от заинтересованите страни за съществено занижени разчети в оценката на въздействие, България настоява Европейската комисия своевременно да предприеме корективни мерки, вкл. значително удължаване на преходните периоди за прилагане. Това е особено необходимо по отношение производството на антибиотици и други генерични лекарствени продукти, които може да бъдат оттеглени от пазара или съществено оскъпени. Очакваните щети за европейската индустрия, потребители и пациенти предполагат своевременно преразглеждане и актуализиране на директивата.

България настоява за проследяване на ефектите от прилагането върху достъпа до лекарствени продукти и за предприемане на своевременни мерки при негативни последици дори само в една държава членка.

В допълнение, изразяваме загриженост, че въведените с разпоредбата относно РОП задължения не са пропорционални на приноса на козметичния сектор към емисиите на микрозамърсители. През 2023 година вече бяха въведени ограничения по отношение употребата на микрочастици от синтетични полимери в козметични продукти с вторично законодателство по линия на Регламента REACH. Индустрията работи по замяната им с разградими алтернативи, което ще намали замърсяването.

Много от засегнатите козметични продукти се произвеждат от МСП, за които РОП ще представлява значителна финансова и административна тежест, включително по отношение на доказване на съответствие с изискванията за освобождаване.

Предвид това, смятаме, че са налице противоречия с принципите на ЕС за опростяване и ненужна тежест.

Statement by Czechia

Czechia supports the revised Urban Wastewater Treatment Directive (UWWTD). We consider the proposal to be an ambitious text which will make it possible to strengthen the protection of human health and the environment, particularly against emerging sources of contamination.

In general Czechia supports the application of the polluter pays principle and the extended producer responsibility (EPR) mechanism to finance the quaternary treatment systems to reduce the presence and discharge of micropollutants into aquatic environments.

Czechia, however, shares concerns of other Member States regarding the application of the EPR systems to medicinal products for human use and its impact on prices and accessibility of these products. We are concerned these effects have not been fully assessed during the Impact assessment, especially in view of the current shortages of medicinal products affecting majority of Member States. We are also concerned about negative impact it may have on the availability of the medicinal products on the EC Critical Medicines list.

Czechia therefore calls for a careful and ongoing evaluation of the impacts of the EPR on the following aspects:

- Financial burden on healthcare systems budgets and patients;
- Availability and choice of treatment;
- Side-effects on the EU's strategic autonomy and global competitiveness;
- Side-effects on the pharmaceutical industry, including on relocation of manufacturing;
- Creation of additional barriers to market entry;
- Unequal conditions of the EPR between Member States.

Should it be apparent that one of the above mentioned areas is disproportionately negatively affected by the introduction of the EPR system, we urge the Commission to seek measures to mitigate these effects, including a possible review of the relevant provisions of the UWWTD. We also call on the Commission to take these aspects into account during the preparations of relevant implementing and delegated acts.

Statement by Germany

Deutschland unterstützt die überarbeitete Kommunalabwasserrichtlinie (UWWTD) als wichtige Maßnahme für einen verbesserten Schutz der Gewässer sowie als Beitrag zur Reduzierung schädlicher Chemikalien in der Umwelt sowie als Beitrag zum Klimaschutz. Deutschland stimmt daher für die Annahme der UWWTD.

Gleichzeitig ist es wichtig, im Sinne der branchenspezifischen erweiterten Herstellerverantwortung (Extended Producer Responsibility - EPR), Anreize für die Verursacher zu schaffen, in die Entwicklung umweltfreundlicherer Produkte zu investieren. Es ist noch unklar, inwieweit diese Anreize insbesondere für generische Arzneimittel Wirkung entfalten können. Die Auswirkungen der erhöhten Kosten durch die EPR, insbesondere für generische Arzneimittel, die mit einem Verordnungsanteil von über 80 Prozent in Deutschland eine überragende Rolle spielen, und mit Blick auf möglicherweise dadurch entstehende Mehrbelastungen der Krankenkassen, sollten besonders in den Blick genommen werden. Die Versorgung der Patientinnen und Patienten und der Zugang zu qualitativ hochwertigen und gleichzeitig erschwinglichen Arzneimitteln sind essenziell. Zudem nehmen, unabhängig von der UWWTD, Lieferengpässe und Abhängigkeiten von der Produktion in Drittstaaten zu. Vor diesem Hintergrund erwartet die Bundesregierung, dass die Europäische Kommission bei sich abzeichnenden negativen Auswirkungen, insbesondere Lieferengpässen und Marktaustritten bei versorgungskritischen Arzneimitteln sowie bei relevanten Mehrbelastungen der Krankenkassenausgaben infolge der Richtlinie, zeitnah Maßnahmen ergreift, die die Versorgung der Patientinnen und Patienten sicherstellen. Hierbei ist eine enge Abstimmung zwischen den Mitgliedstaaten erforderlich, die von der Europäischen Kommission unterstützt und koordiniert werden sollte.

Deutschland als ein wichtiger Standort der Pharmaindustrie spricht sich außerdem für eine frühzeitige Evaluierung im Hinblick auf die erweiterte Herstellerverantwortung aus, auch um wichtige Investitionen, Innovationen und Produktionen in der EU zu halten. In diesem Zusammenhang ist auch eine frühzeitige Überprüfung der Einbeziehung weiterer Sektoren in die EPR wünschenswert. Weiterhin wird es für notwendig gehalten, die EPR einheitlich in Europa umsetzen, um ein Funktionieren des Binnenmarkts sicherzustellen. Dazu gehört nach Auffassung Deutschlands eine einheitliche Liste an Substanzen und ihrer Schädlichkeit sowie die Prüfung einer harmonisierten Festsetzung der Beiträge zur Vermeidung von Marktverzerrungen.

Statement by Estonia

We express serious concerns in relation to the Article 9 on applying the extended producer responsibility (EPR) to pharmaceuticals. While the EPR can be a useful source of funding to cover the costs of wastewater treatment from micropollutants (quaternary treatment), it should not be an obligatory or only solution for the Member States. When applying the EPR, Member States should be able to consider their specific national context regarding technical feasibility and economic viability of setting up the EPR, as well as wider socio-economic implications, in particular the availability and affordability of essential and critical medicinal products. Considering these aspects Member States should be able to decide to a greater extent on the use of alternative or additional funding sources to cover the costs of quaternary treatment and in justified cases be able to exempt certain product categories from the EPR.

Although we agree that the “polluter pays” principle is a necessary underlying concept of environmental protection, we are not convinced it is suitable for pharmaceutical sector in this Directive for the following reasons.

Firstly, **the clear added value of EPR in case of pharmaceuticals has not been confirmed by the feasibility study** (carried out as part of the Commission's impact assessment), as the effect of EPR on behavioural change would be very limited. On one hand, EPR is unlikely to significantly incentivise the substitution of pharmaceutical active ingredients in short- to medium-term, considering their specific innovation cycles. On the other hand, patients do not have the option to decrease their consumption of a medically indicated medicinal product or switch to another product. In this respect, **ethical aspects are not sufficiently considered**, as additional costs will be borne by patients, putting a disproportionate and unfair burden on population groups in a vulnerable situation due to their health condition.

Secondly, we note with concern that the chosen approach of the EPR system will cause **unequal treatment between Member States**. Additional barriers to market entry and price increase of certain pharmaceuticals could significantly worsen the availability and choice of treatment, especially in the context of small markets, which are already faced with frequent market withdrawals due to economic reasons. Furthermore, in Member States without a substantial local pharmaceutical production, the costs will rather be transferred from the manufacturer to other downstream actors. This will not serve the initial aim of producer responsibility, as in these circumstances the costs of EPR will very likely be transferred to the health care budget and increase patients' co-payments. Introducing mandatory EPR will thus have **negative socio-economic implications but also will intrude the Member States' competence** in financing healthcare. Additionally, **economic feasibility and administrative burden** is not sufficiently considered, especially if the number of "producers" is relatively small. In smaller Member States with a lower consumption of pharmaceuticals, introducing EPR will lead to an unreasonable financial burden on a few actors on the market. Allowing to cover up to 20% of the quaternary treatment costs through national financing may not be sufficient to prevent negative impact on the availability and affordability of critical medicines.

Thirdly, we note that it remains unclear **who is the subject of the extended producer responsibility** in the case of pharmaceutical supply chain, which involves many actors who make the product available on the market. Consequently, due to parallel trade this may lead to **double taxation**.

Because of these reasons Estonia is not able to support the Directive of the European Parliament and of the Council concerning urban wastewater treatment and abstains from the vote.

Statement by Greece

The Hellenic Republic welcomes the European Commission's initiative to revise Urban Wastewater Treatment Directive (UWWTD) and supports its recast aiming towards integrated and sustainable water management, reduction of pollution and increased protection of human health and the environment, in alignment with the EU goals and policies.

While Greece shares the environmental objectives of the compromise text of the proposal, we express our concern as regards the new, ambitious requirements. The expansion of the scope in combination with the new obligations are challenging as they will create significant investments demands, increased operational costs, complexity and administrative burden within a strict timeframe. The extension of the population threshold is expected to lead to a very large number of agglomerations in Greece obligated to apply the Directive, mainly due to high fluctuations of their population due to their touristic character. We are concerned about the affordability and sustainability of many future cases where the permanent residents will be very few compared to the equivalent population.

We are particularly thoughtful as regards the application of new requirements such as energy neutrality and extended producer responsibility. As regards EPR, our concerns mainly focus on the complexity and differentiations of its application which may occur in different MS as well as potential impacts in the availability and affordability of medicines.

To fully implement the new Directive, in the required time framework, considerable financial resources will be required. Substantial support will be needed, both as regards EU funding as well as regarding technical support and assistance in organizational, scientific and administrative issues.

We are confident that these concerns will be given due consideration when the new Directive enters into force, enabling Member States to fully and effectively apply its provisions. Despite the aforementioned application concerns, related to the ambitious requirements and goals of the revised Directive, we see the wider vision towards enhanced protection of human health, water resources and the environment in general.

Statement by Spain

España comparte y apoya la ambición ambiental de la Unión Europea, y por ello votará a favor de la revisión de la Directiva de Tratamiento de las Aguas Residuales Urbanas, por considerarla una norma clave para mejorar el estado del medio ambiente y de la salud.

La transposición e implementación del texto supondrá un enorme reto para todos los Estados miembros, no sólo por los nuevos objetivos que en la Directiva se proponen, sino también por lo ajustado de los plazos para cumplirlos. Por ello, será necesario contar con el apoyo de las instituciones europeas a lo largo de todo el proceso.

La introducción del nuevo tratamiento cuaternario para abordar la contaminación generada por los microcontaminantes, y su financiación a través del sistema de responsabilidad ampliada del productor, debe hacerse asegurando que el principio de "quien contamina paga" se aplica de manera equitativa y proporcional. La implementación de dicho tratamiento deberá hacerse de forma que se refuerce el objetivo primordial de eliminar la contaminación en origen, y evitando que el acceso y asequibilidad de los productos incluidos en el Anexo III de la Directiva se vean afectados en su aplicación.

Por ello, España solicita a la Comisión que se establezcan directrices con la mayor brevedad posible, con el fin de garantizar una implementación armonizada entre los distintos Estados miembros, pero que también se dote a éstos de cierta libertad para poder adecuar estos requerimientos a los marcos normativos nacionales.

Los actos delegados a preparar con este fin deberían acompañarse de un estudio de impacto complementario para evaluar los efectos del esquema de la RAP y su efectividad a la hora de reducir la contaminación en la fuente.

Statement by France

La France soutient la directive révisée sur les eaux résiduaires urbaines (UWWTD) et considère celle-ci comme un texte ambitieux, tenant compte des effets du changement climatique, permettant de renforcer la protection de la santé humaine et de l'environnement notamment contre les sources de contamination émergentes. La France soutient l'application du principe pollueur-payeur et le mécanisme de responsabilité élargie du producteur afin de financer la mise en place de systèmes de traitement quaternaire pour réduire la présence et les rejets de micropolluants dans les milieux aquatiques. C'est pourquoi la France confirme sa mobilisation pour atteindre les objectifs de la directive révisée.

Néanmoins, si la directive révisée permettra de créer des incitations afin que nos industriels investissent dans le développement de produits plus respectueux de l'environnement notamment en ce qui concerne les micropolluants, la France sera attentive dans sa mise en œuvre à l'importance d'éviter les effets de bord négatifs pour les industries pharmaceutique et cosmétique afin de ne pas perdre de vue l'objectif primordial du renforcement de l'autonomie stratégique et de la compétitivité mondiale de l'UE. Il est nécessaire que nos industries puissent maintenir leurs investissements et innovations (en particulier dans la production de produits plus responsables) dans nos territoires. S'agissant des médicaments, la mise en œuvre de la directive ne doit pas créer de risques d'accroissement de pénuries en favorisant les délocalisations, dans un contexte de prix régulés.

Enfin, la France invite la Commission à une préparation finement calibrée du futur acte délégué, concernant la définition de la liste des substances qui déterminera le champ des contributeurs à la REP et appelle à ce titre la Commission à ne pas faire peser une charge excessive sur certaines entreprises. La France recommande également de veiller à une mise en œuvre harmonisée entre les différents Etats membres afin de préserver le bon fonctionnement du marché intérieur.

Pour ces raisons, la France veillera à ce que toutes les informations nécessaires soient mises à disposition de la Commission et préconise la réalisation d'une étude d'impact complémentaire ciblée en vue de la préparation de l'acte délégué.

Statement by Italy

L'Italia sostiene l'adozione della Direttiva riveduta sul trattamento delle acque reflue urbane, in particolare le sue componenti innovative che promuoveranno misure per contrastare gli effetti del cambiamento climatico, come il recupero di nutrienti e materiali, l'uso efficiente dell'energia, il riutilizzo delle acque e dei fanghi trattati e il miglioramento della gestione del deflusso urbano.

L'Italia ritiene che l'attuazione della nuova Direttiva sarà molto impegnativa e richiederà notevoli investimenti. Per questo motivo ritiene essenziale e chiede alla Commissione di garantire che siano disponibili fondi UE adeguati per sostenere l'attuazione della Direttiva, in particolare la riconversione energetica del settore delle acque reflue.

L'Italia chiede inoltre che siano avviati al più presto i lavori di aggiornamento della valutazione d'impatto della Commissione, al fine di facilitare una tempestiva revisione delle disposizioni sulla Responsabilità estesa del produttore (EPR) della Direttiva e di estendere successivamente il regime EPR a settori diversi da quello farmaceutico e cosmetico, garantendo così la piena attuazione del principio “chi inquina paga”.

Statement by Cyprus

The Republic of Cyprus shares the overall environmental objectives of the Urban Wastewater Treatment Directive, and thus supports the adoption of the Urban wastewater treatment Directive (recast).

However, the current Directive has been proven very difficult in its implementation, and therefore, Cyprus maintains legitimate concerns associated with the increased administrative burden, the significant financial costs, and the rather limited timeframe for Cyprus' compliance with the more ambitious requirements of the new Directive.

It is pertinent to recall that Cyprus has the following unique characteristics: the absence of rivers or lakes, the great depth of groundwater (in many cases more than 100 meters deep) and the fact that most of the treated wastewater is already used for agricultural irrigation. In fact, River Basin Management Plans of Cyprus confirm that in most cases no water bodies are negatively affected from wastewater discharges.

The challenges we are confronted with the implementation of the current Directive, despite our best efforts and genuine political commitment, are telling of how difficult it will be to implement the new Directive that significantly raised the ambition. In particular, thus far we were not able to comply with the requirements of the current Directive for 28 agglomerations out of a total of 57 agglomerations. The delays encountered are linked to the enormous economic costs, the heavy administrative burden, the discovery of archaeological findings during the works and the need for extensive government coordination and consultations with local authorities. Our revised National Implementation Programme (NIP-2020) submitted to the European Commission on 30 June 2022 and the latest revised National Implementation Programme (NIP-2022) submitted to the European Commission on 30 June 2024, set 2030 as the end date for full compliance with Directive 91/271/EEC.

The new threshold of agglomerations of 1 000 p.e., will render it very difficult for Cyprus to find the necessary resources to construct collecting systems and secondary treatment in 26 additional agglomerations. It should be noted that due to the size of our country, we have a very limited number of contractors that can execute the required systems.

Despite the serious implementation difficulties, Cyprus supports the adoption of the Urban wastewater treatment Directive (recast) because we understand its importance for protecting the environment and human health.

Cyprus is confident that these concerns will be given due consideration when the new Directive enters into force, including through safeguarding sufficient EU funding that will enable Member States in meeting the Directive's significant financial requirements.

Statement by Latvia

Latvia supports the Directive concerning urban wastewater treatment, which aims to better protect the environment and human health. During the negotiations, Latvia has repeatedly expressed support for updating of the requirements on wastewater collection and treatment, as well as on the increasing sustainability and efficiency of the wastewater management sector.

However, it should be noted that the implementation of the Directive is associated with significant challenges.

In general, Latvia believes that the extended producer responsibility (EPR) system is an effective tool for implementing the polluter-pays principle. However, neither Latvia, nor other countries have previously established the EPR system in the field of wastewater management and have not applied the EPR system to pharmaceuticals. We share the concerns of other Member States regarding the application of the EPR systems to medicinal products for human use and possible impact on prices and accessibility of these products for the most vulnerable population. We are also concerned that these impacts have not been fully assessed during the Impact assessment, nor were the current shortages of medicinal products affecting many Member States properly considered. Therefore, we invite the Commission to continue evaluating these impacts also after the adoption, and act accordingly, if necessary.

We still believe that achieving energy neutrality will be very challenging, particularly for smaller urban wastewater treatment plants, for which not all renewable energy sources are technically and economically feasible.

Finally, we must keep in mind the enormous future costs required to ensure that wastewater management infrastructure meets the requirements of this directive. The implementation will demand substantial investments over the next 15-20 years, amounting to at least several billion euros in Latvia. These costs cannot be fully borne by the users of wastewater management services alone. We will continue to emphasize the need to ensure appropriate financial resources, including from the next Multiannual Financial Framework.

Statement by Lithuania

Lithuania supports the recast of the Directive on Urban Wastewater Treatment, which aligns with the EU's goals for environmental protection and water quality. Lithuania supports the Directive's focus on improving wastewater treatment infrastructure and reducing pollution, both of which are critical for safeguarding our water resources.

However, Lithuania finds that the current level of ambition, particularly regarding the implementation timelines and resource allocation, is excessively high. This poses significant challenges, especially for Member States with diverse infrastructures and varying economic capacities. Lithuania must acknowledge that even the current Directive (91/271/EEC) has been challenging to fully implement, and many Member States, including Lithuania, are still working towards compliance. This makes the heightened ambition of the revised Directive even more difficult to achieve.

The extension of the scope, particularly the obligation to connect all agglomerations from 1 000 p.e., places a significant financial burden on Lithuania. Given its geographical and demographic situation, especially in smaller settlements where population decline due to migration is a reality, the installation of wastewater collection systems may have a negligible impact in reducing and preventing pollution. In these cases, the investment is not justified from an economic standpoint.

Lithuania also accepts the common goal to implement the principle of Extended Producer Responsibility (EPR) more effectively. However, Lithuania questions the rationale for applying the EPR principle exclusively to the pharmaceutical and cosmetics industries. Lithuania notes that the Directive's impact assessment on pharmaceutical industry, including the accessibility and pricing of medicinal products, has not been fully assessed, particularly in the context of current shortages of medicinal products and ongoing efforts to ensure autonomy of the EU's pharmaceutical industry. Lithuania strongly believes that the Directive should cover all sectors emitting micropollutants to ensure a comprehensive and fair application of the "polluter pays" principle. Lithuania is concerned about the feasibility and enforceability of these provisions and how they will affect not only its manufacturers in these sectors but also supplies of the important products from other member states. Concerning EPR, Lithuania would have preferred that the costs of quaternary treatment be shared more equitably through a stronger application of the "polluter pays" principle.

Finally, it is important to emphasise that the implementation of the new Directive will require considerable financial resources. Like many other Member States, Lithuania faces challenges with funding the necessary infrastructure upgrades and operational costs. The ambition of the Directive cannot be met without substantial financial support, and Lithuania stresses the need for dedicated EU funding to assist Member States in meeting the requirements of the Directive. Without this financial backing, the feasibility of implementing the Directive, especially in smaller Member States, is questionable.

Statement by Malta

Malta has always acknowledged and supported the Commission's ambition to address the source of pollution in our waters and ultimately, achieve zero pollution in the European Union.

While, from an implementation perspective, Malta understands the rationale behind Extended Producer Responsibility (EPR) schemes and whilst acknowledging the benefits that such schemes bring, Malta remains of the opinion that having patients bear the ultimate financial burden is not acceptable. In this regard, Malta positively acknowledges the amendments introduced to the Directive to enable the necessary flexibilities to address the potential impacts of EPR schemes on the accessibility, availability and affordability of medicines at the national level, by enabling Member States to finance part of the costs of the quaternary treatment in case such impacts occur.

Having said this, Malta believes that ambition must not come at a disproportionate social cost. In line with the position adopted from the beginning of the negotiations in Council, Malta still has a major political concern on the application of the proposed extension of the EPR to cover all medicines in Annex III. Patients undergoing treatment have little to no control over the manner in which they receive such treatment, much less choice over the type of medication prescribed. The current text, whilst significantly increasing the flexibility through which EPR schemes can be developed in the respective Member States, still does not provide enough safeguards to ensure that the financial impact (even if marginal) on the pharmaceutical industry will not trickle down to patients.

Malta believes that price increase of certain pharmaceuticals would significantly worsen the availability and choice of treatment, particularly for a small market like Malta's market. This would ultimately make it even worse for patients, who are the most vulnerable.

It is in this spirit that whilst continuing to believe that in the European Union's pursuit of a better-quality water, Malta affirms that this Directive should not jeopardise the accessibility, availability and affordability of vital products such as medicines which are a necessity and not a luxury.

Statement by Austria

Österreich unterstützt die Ausrichtung der überarbeiteten kommunalen Abwasserrichtlinie (UWWTD) und sieht diese als wichtige Maßnahme für einen langfristigen und nachhaltigen Schutz der Wasserqualität. Daher stimmt Österreich auch für die Annahme der UWWTD. Gleichzeitig ist es wichtig, im Sinne der branchenspezifischen erweiterten Herstellerverantwortung (EPR), Anreize für die Verursacher zu schaffen und in die Entwicklung umweltfreundlicherer Produkte zu investieren. Österreich weist vor diesem Hintergrund auf die Bedenken der pharmazeutischen und kosmetischen Industrie hin, und würde sich für eine frühzeitige Evaluierung in Hinblick auf die erweiterte Herstellerverantwortung aussprechen.

Dies würde auch zur übergeordneten Zielsetzung hinsichtlich der Stärkung der strategischen Autonomie sowie der globalen Wettbewerbsfähigkeit der EU in sensiblen Sektoren beitragen und wichtige Investitionen, Innovationen und Produktion - beispielsweise im Arzneimittelbereich – in der EU halten.

Statement by Poland

Polska dostrzega potrzebę nowelizacji obecnie obowiązującej dyrektywy dotyczącej oczyszczania ścieków komunalnych.

Polska popiera szerszą wizję Komisji Europejskiej w zakresie nowych regulacji. Ambicje zawarte w Europejskim Zielonym Ładzie i innych politykach europejskich powinny zostać uwzględnione w nowych przepisach dotyczących oczyszczania ścieków. Polski sektor wodno-kanalizacyjny angażuje się w wiele aktywności dotyczących: działań na rzecz klimatu, efektywności energetycznej, gospodarki o obiegu zamkniętym i ambicji „zero zanieczyszczeń”. Pomimo nowych bieżących działań, jednym z największych wyzwań jest nadal zapewnienie pełnej zgodności z istniejącą dyrektywą w sprawie ścieków komunalnych (91/271/EWG]. Nadal potrzebne są ogromne inwestycje i wiele kosztownych działań dotyczących: rozbudowy sieci kanalizacyjnej, modernizacji oczyszczalni ścieków, kontroli systemów indywidualnych i odpowiedniego zarządzania.

Tekst kompromisowy dyrektywy dotyczącej oczyszczania ścieków komunalnych wskazuje na wysoki poziom ambicji. Nowa dyrektywa wymagać będzie zarówno długich terminów na wdrożenie (np. na realizację inwestycji), jak również wysokich nakładów finansowych oraz dużych wysiłków organizacyjnych. Ponadto ważne jest zapewnienie środków unijnych na nowe obowiązki wynikające z dyrektywy.

Polska wyraża zaniepokojenie zaostreniem wymogów i skróceniem terminów w porównaniu z osiągniętym kompromisem w ramach Podejścia ogólnego, przyjętego 16 października 2023 r.

Polska podtrzymuje swoje obawy dotyczące wykonalności przepisów umożliwiających skuteczne stosowanie rozszerzonej odpowiedzialności producenta (ROP), biorąc pod uwagę fakt, iż proponowana dyrektywa nie obejmuje wszystkich sektorów emitujących mikrozanieczyszczenia (lecz tylko dwa: kosmetyczny i farmaceutyczny), zapewniając realną realizację zasady „prawdziwie zanieczyszczający płaci”.

Ponadto, rozszerzenie dyrektywy na aglomeracje o RLM od 1 000 do 2 000 spowoduje konieczność realizacji ogromnych inwestycji i wysokie koszty operacyjne, które również będą miały wpływ na taryfy za odbiór ścieków.

Dodatkowo, katastrofalne skutki powodzi w Polsce powodują potrzebę znacznego zaangażowania środków finansowych na odbudowę infrastruktury. W tym świetle, trudne będzie spełnienie wymogów ww. dyrektywy, które także będą wiązały się z poniesieniem znacznych wydatków finansowych.

Biorąc powyższe pod uwagę, Polska nie może poprzeć projektu dyrektywy i głosuje przeciw jego przyjęciu.

Statement by Portugal

Portugal apoia plenamente os objetivos da Diretiva relativa ao tratamento de águas residuais urbanas, reconhecendo-a como um passo ambicioso e essencial para melhorar a proteção das massas de água, enfrentar os desafios das alterações climáticas e alcançar os objetivos da Diretiva-Quadro da Água (DQA).

Portugal acredita que a diretiva reforçará a proteção da saúde humana e do ambiente, particularmente na mitigação de fontes emergentes de contaminação.

No entanto, Portugal reconhece que a aplicação bem-sucedida da diretiva será um desafio, exigindo investimentos consideráveis e um conhecimento profundo das abordagens baseadas no risco. Uma das principais dificuldades reside na avaliação dos extravasamentos de águas pluviais em termos de cargas poluentes, o que exigirá técnicas de avaliação sofisticadas. Além disso, a aplicação da responsabilidade alargada do produtor (RAP) representa um desafio significativo.

Portugal salienta a importância de assegurar um intercâmbio sólido de informações entre os Estados-Membros para evitar incoerências na aplicação da RAP, em especial no que diz respeito ao sector farmacêutico. As discrepâncias podem ter um impacto negativo nos mercados internos, pelo que o alinhamento entre países será crucial. As indústrias devem continuar a manter os seus investimentos e inovação, especialmente na produção de produtos mais responsáveis dentro do país. A manutenção de um equilíbrio entre os objetivos ambientais e a competitividade industrial será fundamental para garantir um progresso sustentável.

Apesar destes desafios, Portugal continua empenhado em contribuir de forma significativa para os objetivos da diretiva. Portugal está empenhado em promover a cooperação e a partilha de conhecimentos com outros Estados-Membros para garantir o êxito da aplicação da diretiva. Esta abordagem cooperativa será fundamental para ultrapassar as dificuldades associadas à RAP e para fazer avançar os objetivos de proteção ambiental da diretiva.

Em conclusão, Portugal está totalmente empenhado no sucesso da diretiva, preparado para dar contributos significativos e empenhar-se em esforços de colaboração para reforçar a proteção ambiental e a saúde pública em toda a Europa. Por conseguinte, Portugal apoia a adoção da Diretiva relativa ao tratamento de águas residuais urbanas.

Statement by Romania

Romania expresses its support for the final compromise text of the proposal for a Directive of the European Parliament and of the Council concerning Urban Wastewater Treatment (recast). While we endorse the proposal's overarching goal of aligning urban wastewater treatment with the latest scientific developments and the objectives of the Zero Pollution Action Plan, we would like to highlight that certain requirements will be challenging and costly to implement.

We emphasise that the successful execution of the Directive will require significant investments over an extended period, which will impact the availability and affordability of wastewater management services, mostly in rural areas. This is particularly crucial given that substantial work remains to fully implement the current Directive (91/271/EEC). We appreciate that the new Directive acknowledges the unique challenges faced by Member States that joined the Union more recently, including Romania.

The implementation and enforcement of the Directive will require funding from diverse sources, including substantial financial support from national and European Union funds. Additionally, broadening the scope to include agglomerations with populations between 1 000 and 2 000 will demand considerable investments and lead to higher operational costs. We wish to highlight a specific national concern: due to declining population trends, the lowered threshold increases the likelihood that some agglomerations may soon fall below this limit, which could compromise cost efficiency and drive up unnecessary expenses.

Romania also has reservations regarding the impact of the extended producer responsibility (EPR) provisions, particularly as they pertain to pharmaceuticals. From the intensive discussions we have had with the industry the implementation of EPR will lead to extremely high costs which will affect the availability and affordability of medicines, particularly generic ones. Such a situation could lead to a health crisis for our population. From the outset, we have underlined the necessity of implementing the EPR at the EU level to ensure equitable treatment among Member States. Therefore, we urge the Commission to facilitate discussions aimed at achieving a uniform implementation of the EPR across all Member States, ensuring that it does not impose undue burdens on populations in need of medicines.

Statement by Slovenia

Slovenia supports and commits to the objectives of the Directive concerning urban wastewater treatment (recast) that will contribute to the reduction of emissions of substances into water as well as to the reduction of greenhouse gas emissions, to efficient use of energy and to the promotion of a circular economy by encouraging the reuse of treated wastewater and sludge and nutrient processing.

Slovenia welcomes the agreed extension of the deadlines for the implementation of the new or enhanced requirements of the directive. However, Slovenia believes that some of the objectives are very ambitious and some technically and economically very demanding measures will be needed to achieve them. Therefore, Slovenia urges the Commission to ensure sufficient EU funds to support the efforts of Member States.

Slovenia welcomes the ambitions in providing appropriate infrastructure for the collection and treatment of urban wastewater, as well as lowering of the threshold for agglomerations' size falling under the scope of this directive. At the same time Slovenia welcomes the provisions that allow for some flexibility according to specific national or local, especially geographic circumstances, or other specific local conditions. However, Slovenia is of the opinion that even more flexibility would be needed regarding the use of individual systems for the collection and treatment of urban wastewater. We emphasise our specific concern regarding the vague requirement to achieve the same level of environmental and human health and environmental protection that has to be achieved by individual systems, as well as regarding the uniform threshold of 2 % for the use of individual systems at national level that does not take into account the variety of circumstances at EU, national, or local levels.

Slovenia supports the enhanced implementation of the “polluter pays” principle. Nevertheless, Slovenia recalls concerns that the requirements on the extended producer responsibility are not sufficiently clear. In this respect Slovenia welcomes the obligation of the Commission to provide an exchange of information and is looking forward to exchanging experience and good practices.

Slovenia also points out that the implementation of the new obligation for the quaternary treatment and the achievement of the objectives in this regard will be a significant challenge at national level. Same goes for the ambitions on achieving energy neutrality of this sector. Slovenia believes that the contribution of this sector to the achievement of climate goals is necessary, and from this point of view supports the efforts to improve energy efficiency within the sector. However, Slovenia would like to recall its concerns as regards the feasibility of achieving energy neutrality within the sector at national level.

In addition, Slovenia recalls its concerns regarding the ambitious requirements for information collection and management of that information.

Despite serious concerns related to the ambitious objectives mentioned above, Slovenia nevertheless recognises the revised directive as an important step towards an enhanced protection of environment and human health, and thus votes for the adoption of this Directive.